Performance of Reti-cardiovascular disease in identifying intermediate- and high-risk groups according to modified framingham risk score in different ethnicities in the SEED study
| Population/metrics . | All participants . | Female . | Male . |
|---|---|---|---|
| Chinese | |||
| ȃPrevalence | 26.0% (24.0–27.1%) | 6.8% (5.6–8.2%) | 45.0% (43.0–47.7%) |
| ȃSensitivity | 79.7% (76.6–82.5%) | 92.2% (85.1–96.6%) | 77.7% (74.3–80.9%) |
| ȃSpecificity | 78.5% (76.7–80.2%) | 84.3% (82.3–86.2%) | 68.0% (64.6–71.2%) |
| ȃPPV | 55.9% (52.9–58.9%) | 30.0% (25.0–35.4%) | 66.6% (63.1–70.0%) |
| ȃNPV | 91.9% (90.5–93.1%) | 99.3% (98.7–99.7%) | 78.8% (75.5–81.8%) |
| Indian | |||
| ȃPrevalence | 56.0% (55.0–58.3%) | 38.0%(35.0–40.1%) | 76.0%(74.0–78.6%) |
| ȃSensitivity | 83.2% (81.3–85.0%) | 81.0% (77.5–84.2%) | 84.3% (82.0–86.4%) |
| ȃSpecificity | 78.6% (76.2–80.9%) | 83.1% (80.6–85.5%) | 66.1% (60.7–71.2%) |
| ȃPPV | 83.5% (81.6–85.3%) | 74.3% (70.6–77.7%) | 88.9% (86.8–90.8%) |
| ȃNPV | 78.2% (75.9–80.5%) | 87.9% (85.6–90.0%) | 56.5% (51.4–61.5%) |
| Malay | |||
| ȃPrevalence | 48.0% (46.0–50.0%) | 32.0% (30.0–34.7%) | 66.0% (63.0–68.5%) |
| ȃSensitivity | 82.1% (80.1–84.1%) | 81.9% (78.2–85.1%) | 82.3% (79.7–84.7%) |
| ȃSpecificity | 85.2% (83.3–87.0%) | 88.0% (85.9–89.9%) | 78.9% (75.0–82.5%) |
| ȃPPV | 83.8% (81.7–85.7%) | 76.6% (72.8–80.1%) | 88.3% (86.0–90.4%) |
| ȃNPV | 83.7% (81.8–85.5%) | 91.0% (89.1–92.7%) | 69.7% (65.6–73.6%) |
| Population/metrics . | All participants . | Female . | Male . |
|---|---|---|---|
| Chinese | |||
| ȃPrevalence | 26.0% (24.0–27.1%) | 6.8% (5.6–8.2%) | 45.0% (43.0–47.7%) |
| ȃSensitivity | 79.7% (76.6–82.5%) | 92.2% (85.1–96.6%) | 77.7% (74.3–80.9%) |
| ȃSpecificity | 78.5% (76.7–80.2%) | 84.3% (82.3–86.2%) | 68.0% (64.6–71.2%) |
| ȃPPV | 55.9% (52.9–58.9%) | 30.0% (25.0–35.4%) | 66.6% (63.1–70.0%) |
| ȃNPV | 91.9% (90.5–93.1%) | 99.3% (98.7–99.7%) | 78.8% (75.5–81.8%) |
| Indian | |||
| ȃPrevalence | 56.0% (55.0–58.3%) | 38.0%(35.0–40.1%) | 76.0%(74.0–78.6%) |
| ȃSensitivity | 83.2% (81.3–85.0%) | 81.0% (77.5–84.2%) | 84.3% (82.0–86.4%) |
| ȃSpecificity | 78.6% (76.2–80.9%) | 83.1% (80.6–85.5%) | 66.1% (60.7–71.2%) |
| ȃPPV | 83.5% (81.6–85.3%) | 74.3% (70.6–77.7%) | 88.9% (86.8–90.8%) |
| ȃNPV | 78.2% (75.9–80.5%) | 87.9% (85.6–90.0%) | 56.5% (51.4–61.5%) |
| Malay | |||
| ȃPrevalence | 48.0% (46.0–50.0%) | 32.0% (30.0–34.7%) | 66.0% (63.0–68.5%) |
| ȃSensitivity | 82.1% (80.1–84.1%) | 81.9% (78.2–85.1%) | 82.3% (79.7–84.7%) |
| ȃSpecificity | 85.2% (83.3–87.0%) | 88.0% (85.9–89.9%) | 78.9% (75.0–82.5%) |
| ȃPPV | 83.8% (81.7–85.7%) | 76.6% (72.8–80.1%) | 88.3% (86.0–90.4%) |
| ȃNPV | 83.7% (81.8–85.5%) | 91.0% (89.1–92.7%) | 69.7% (65.6–73.6%) |
CVD; cardiovascular disease; SEED; Singapore Eye Epidemiology Diseases; Reti-CVD; deep-learning-based retinal CVD imaging biomarker; PPV; positive predictive value; NPV; negative predictive value.
Performance of Reti-cardiovascular disease in identifying intermediate- and high-risk groups according to modified framingham risk score in different ethnicities in the SEED study
| Population/metrics . | All participants . | Female . | Male . |
|---|---|---|---|
| Chinese | |||
| ȃPrevalence | 26.0% (24.0–27.1%) | 6.8% (5.6–8.2%) | 45.0% (43.0–47.7%) |
| ȃSensitivity | 79.7% (76.6–82.5%) | 92.2% (85.1–96.6%) | 77.7% (74.3–80.9%) |
| ȃSpecificity | 78.5% (76.7–80.2%) | 84.3% (82.3–86.2%) | 68.0% (64.6–71.2%) |
| ȃPPV | 55.9% (52.9–58.9%) | 30.0% (25.0–35.4%) | 66.6% (63.1–70.0%) |
| ȃNPV | 91.9% (90.5–93.1%) | 99.3% (98.7–99.7%) | 78.8% (75.5–81.8%) |
| Indian | |||
| ȃPrevalence | 56.0% (55.0–58.3%) | 38.0%(35.0–40.1%) | 76.0%(74.0–78.6%) |
| ȃSensitivity | 83.2% (81.3–85.0%) | 81.0% (77.5–84.2%) | 84.3% (82.0–86.4%) |
| ȃSpecificity | 78.6% (76.2–80.9%) | 83.1% (80.6–85.5%) | 66.1% (60.7–71.2%) |
| ȃPPV | 83.5% (81.6–85.3%) | 74.3% (70.6–77.7%) | 88.9% (86.8–90.8%) |
| ȃNPV | 78.2% (75.9–80.5%) | 87.9% (85.6–90.0%) | 56.5% (51.4–61.5%) |
| Malay | |||
| ȃPrevalence | 48.0% (46.0–50.0%) | 32.0% (30.0–34.7%) | 66.0% (63.0–68.5%) |
| ȃSensitivity | 82.1% (80.1–84.1%) | 81.9% (78.2–85.1%) | 82.3% (79.7–84.7%) |
| ȃSpecificity | 85.2% (83.3–87.0%) | 88.0% (85.9–89.9%) | 78.9% (75.0–82.5%) |
| ȃPPV | 83.8% (81.7–85.7%) | 76.6% (72.8–80.1%) | 88.3% (86.0–90.4%) |
| ȃNPV | 83.7% (81.8–85.5%) | 91.0% (89.1–92.7%) | 69.7% (65.6–73.6%) |
| Population/metrics . | All participants . | Female . | Male . |
|---|---|---|---|
| Chinese | |||
| ȃPrevalence | 26.0% (24.0–27.1%) | 6.8% (5.6–8.2%) | 45.0% (43.0–47.7%) |
| ȃSensitivity | 79.7% (76.6–82.5%) | 92.2% (85.1–96.6%) | 77.7% (74.3–80.9%) |
| ȃSpecificity | 78.5% (76.7–80.2%) | 84.3% (82.3–86.2%) | 68.0% (64.6–71.2%) |
| ȃPPV | 55.9% (52.9–58.9%) | 30.0% (25.0–35.4%) | 66.6% (63.1–70.0%) |
| ȃNPV | 91.9% (90.5–93.1%) | 99.3% (98.7–99.7%) | 78.8% (75.5–81.8%) |
| Indian | |||
| ȃPrevalence | 56.0% (55.0–58.3%) | 38.0%(35.0–40.1%) | 76.0%(74.0–78.6%) |
| ȃSensitivity | 83.2% (81.3–85.0%) | 81.0% (77.5–84.2%) | 84.3% (82.0–86.4%) |
| ȃSpecificity | 78.6% (76.2–80.9%) | 83.1% (80.6–85.5%) | 66.1% (60.7–71.2%) |
| ȃPPV | 83.5% (81.6–85.3%) | 74.3% (70.6–77.7%) | 88.9% (86.8–90.8%) |
| ȃNPV | 78.2% (75.9–80.5%) | 87.9% (85.6–90.0%) | 56.5% (51.4–61.5%) |
| Malay | |||
| ȃPrevalence | 48.0% (46.0–50.0%) | 32.0% (30.0–34.7%) | 66.0% (63.0–68.5%) |
| ȃSensitivity | 82.1% (80.1–84.1%) | 81.9% (78.2–85.1%) | 82.3% (79.7–84.7%) |
| ȃSpecificity | 85.2% (83.3–87.0%) | 88.0% (85.9–89.9%) | 78.9% (75.0–82.5%) |
| ȃPPV | 83.8% (81.7–85.7%) | 76.6% (72.8–80.1%) | 88.3% (86.0–90.4%) |
| ȃNPV | 83.7% (81.8–85.5%) | 91.0% (89.1–92.7%) | 69.7% (65.6–73.6%) |
CVD; cardiovascular disease; SEED; Singapore Eye Epidemiology Diseases; Reti-CVD; deep-learning-based retinal CVD imaging biomarker; PPV; positive predictive value; NPV; negative predictive value.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
